Aug 29, 2011 by Brian Orelli, PhDDrug Approved for Few Patients -- but That's OKThe age of personalized medicine is upon us.
Aug 29, 2011 by Brian Orelli, PhDWe Can Make More! Too Bad Few Want ItDendreon is no longer constrained by its supply.
Aug 26, 2011 by Brian Orelli, PhDWill the FDA Approve NuPathe's Zelrix?FDA will make a decision on Monday … maybe.
Aug 24, 2011 by Brian Orelli, PhDGrowth, but Not Great GrowthMedtronic's growth comes with lower margins.
Aug 24, 2011 by Brian Orelli, PhDCan Roche and Merck Succeed Where Pfizer Failed?CETP inhibitors are lucrative but risky.
Aug 22, 2011 by Brian Orelli, PhDSpeedy in SeattleSeattle Genetics gets an early approval of Adcentris.
Aug 18, 2011 by Brian Orelli, PhDRunning the Correct Trial Isn't EnoughYou need data to support an approval.
Aug 16, 2011 by Brian Orelli, PhDKeeping Those Little Blue Pill Sales UpPfizer wins a patent lawsuit for Viagra.
Aug 15, 2011 by Brian Orelli, PhDAnother Partner, but Still No DataSequenom signs up a European partner.
Aug 15, 2011 by Brian Orelli, PhDThe Same Is Good Enough, for NowGilead's quad meets its endpoint in its first phase 3 trial.
Aug 11, 2011 by Brian Orelli, PhDAmarin Gets 1 Step Closer to the Big TimeAmarin can start its outcomes study.
Aug 10, 2011 by Brian Orelli, PhDA Jab a Month Is All We AskBiogen and Abbott's new long-acting multiple sclerosis drug works, but it has side effects.
Aug 10, 2011 by Brian Orelli, PhDInsiders Are Buying Biotech. Should You?It's an endorsement, but binary events are still hard to predict.
Aug 9, 2011 by Brian Orelli, PhDSome Potential Good News in BiotechThe FDA should approve Gilead's Btripla.
Aug 4, 2011 by Brian Orelli, PhDDendreon Down 65%! What's Next?What caused Dendreon's shocking collapse?
